Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $26.7652W HIGH $59.30
Volume
1.62 M
Value Traded
94.23 M
Short % Float
21.29%
+2.71%Week
-0.04%1 Month
+0.65%3 Month
+63.87%6 Month
+16.73%5 Year
-99.95%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
8.48 B
EPS (TTM)
2.88
P/E Ratio
19.20
Ent. Value
8.67 B
Total Shares
153.09 M
Float Shares
141.64 M
Insiders
7.47%
Institutions
72.91%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PoA blends historical approval base rates, trial design score and FDA review track record.
TGTX Catalyst Timeline
Dated clinical, regulatory and corporate events for TG Therapeutics, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for TG Therapeutics, Inc.
524Total events
14Upcoming
127Tier-1 (high impact)
2006 to 2028Coverage
Upcoming catalysts 2
Event history 50
●R&D DayPresentation
TG Therapeutics to participate in H.C. Wainwright 28th Annual Global Investment Conference fireside chat
▲Quarterly UpdateCorporate
Reported Q2 2026 financial results and raised full year 2026 revenue guidance
▲Topline ReadoutBRIUMVIApprovedClinical Data
Positive topline results from Phase 3 ENHANCE trial of consolidated single infusion regimen for BRIUMVI
relapsing multiple sclerosis (RMS)source ↗
▲Primary Endpoint MetBRIUMVIApprovedClinical Data
ENHANCE trial met primary endpoint of bioequivalence
relapsing multiple sclerosis (RMS)source ↗
▲Trial InitiationBRIUMVIApprovedTrial
Initiated Phase 2 trial of BRIUMVI in treatment-resistant schizophrenia
treatment-resistant schizophreniasource ↗
▲PK PD DataBRIUMVIApprovedClinical Data
Positive PK, PD, safety, and tolerability data from Phase 1 trial of subcutaneous BRIUMVI
relapsing multiple sclerosis (RMS)source ↗
▲Trial InitiationBRIUMVIApprovedTrial
Initiation of Phase 2 trial evaluating BRIUMVI in treatment-resistant schizophrenia
treatment-resistant schizophreniasource ↗
◆Timing GuidanceBRIUMVIApprovedPresentation
Supplemental BLA submission targeted for consolidated dosing regimen
relapsing forms of multiple sclerosissource ↗
◆Oral PresentationPresentation
TG Therapeutics to participate in Goldman Sachs 47th Annual Healthcare Conference fireside chat
▲Topline ReadoutBRIUMVIApprovedClinical Data
Positive topline Phase 1 data for subcutaneous BRIUMVI in MG
myasthenia gravissource ↗
▲Trial InitiationBRIUMVIApprovedTrial
Initiation of Phase 2 trial evaluating BRIUMVI as maintenance therapy after efgartigimod induction
myasthenia gravissource ↗
◆Oral PresentationPresentation
TG Therapeutics to participate in Jefferies Global Healthcare Conference fireside chat
▲Topline ReadoutBRIUMVIApprovedClinical Data
Positive Phase 1 results for subcutaneous BRIUMVI
relapsing multiple sclerosissource ↗
▲Enrollment CompleteBRIUMVIApprovedTrial
Phase 3 subcutaneous BRIUMVI trial enrollment completed
relapsing multiple sclerosissource ↗
◆Oral PresentationBRIUMVIApprovedPresentation
Oral presentation of ENABLE Phase 4 study results on patient-reported outcomes
relapsing forms of multiple sclerosissource ↗
◆Poster PresentationBRIUMVIApprovedPresentation
Poster presentation on ublituximab infusion tolerability from ULTIMATE Phase 3 studies
relapsing forms of multiple sclerosissource ↗
▲Primary Endpoint MetBRIUMVIApprovedClinical Data
ENHANCE Phase 3 trial met primary endpoint of bioequivalence for consolidated single infusion regimen
relapsing forms of multiple sclerosissource ↗
◆Quarterly UpdateCorporate
First Quarter 2026 Financial Results and Business Update Conference Call
▲Enrollment CompleteBRIUMVIApprovedTrial
Completed patient enrollment into ENHANCE trial evaluating consolidated Day 1 and Day 15 dosing regimen for IV BRIUMVI
relapsing multiple sclerosissource ↗
▲Equity OfferingCorporate
Secured $500 million non-dilutive capital from Blue Owl Capital and expanded share repurchase program
◆Poster PresentationBRIUMVIApprovedPresentation
Real World Clinical Experience from ENABLE, the First Phase 4 Observational Study for Patients with Relapsing Multiple Sclerosis Initiating Ublituximab
relapsing forms of multiple sclerosissource ↗
◆Topline ReadoutBRIUMVIApprovedClinical Data
Topline Phase 3 data for ENHANCE trial combining Day 1 and Day 15 doses of IV BRIUMVI
relapsing multiple sclerosissource ↗
▲Quarterly UpdateBRIUMVIApprovedCorporate
Second quarter 2026 BRIUMVI US net product revenue target provided
▲Full ResultsBRIUMVIApprovedClinical Data
Publication of post hoc pooled analysis of ULTIMATE I and II in Neurology and Therapy
highly active relapsing multiple sclerosissource ↗
▲PublicationBRIUMVIApprovedPresentation
Publication: Efficacy of Ublituximab in People with Highly Active Relapsing Multiple Sclerosis in Neurology and Therapy
Highly Active Relapsing Multiple Sclerosissource ↗
◆Quarterly UpdateCorporate
Q4 and FY2025 Financial Results and Business Update Conference Call
▲Full ResultsBRIUMVIApprovedClinical Data
Five-year data from ULTIMATE I and II OLE published in JAMA Neurology
relapsing forms of multiple sclerosissource ↗
●Poster PresentationBRIUMVIApprovedPresentation
Multi-protein Biomarker Test Results for Participants Treated with Ublituximab from the Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab (ENHANCE)
Relapsing Multiple Sclerosissource ↗
▲PublicationBRIUMVIApprovedPresentation
Publication: Five Years of Ublituximab in Multiple Sclerosis: ULTIMATE I and II Open-Label Extension Study in JAMA Neurology
Relapsing Multiple Sclerosissource ↗
◆Oral PresentationPresentation
TG Therapeutics presentation at 44th Annual J.P. Morgan Healthcare Conference
▲Quarterly UpdateCorporate
2026 total global revenue guidance of approximately $875-900 million
◆Oral PresentationPresentation
Participation in 8th Annual Evercore Healthcare Conference fireside chat
◆Oral PresentationPresentation
Participation in TD Cowen Immunology & Inflammation Summit fireside chat
◆Quarterly UpdateCorporate
Third Quarter 2025 Financial Results and Business Update Conference Call
▲Equity OfferingCorporate
Completed initial $100M share repurchase program and authorized additional $100M program
▲Enrollment CompleteBRIUMVIApprovedTrial
Enrollment completed in randomized cohort of Phase 3 ENHANCE trial evaluating consolidated Day 1 and Day 15 dosing schedule for BRIUMVI
relapsing forms of multiple sclerosissource ↗
▲Quarterly UpdateBRIUMVIApprovedCorporate
Preliminary Q4 2025 BRIUMVI U.S. net product revenue of ~$182 million
relapsing forms of multiple sclerosissource ↗
◆Oral PresentationBRIUMVIApprovedPresentation
Long-term Efficacy and Safety of Ublituximab in Relapsing Multiple Sclerosis: Results from Six Years of ULTIMATE I and II Open-label Extension
relapsing forms of multiple sclerosissource ↗
◆Poster PresentationBRIUMVIApprovedPresentation
Real-World Clinical Experience from ENABLE: the First Phase 4 Observational Study for Patients with Relapsing Multiple Sclerosis Initiating Ublituximab
relapsing forms of multiple sclerosissource ↗
◆Oral PresentationPresentation
TG Therapeutics to participate in H.C. Wainwright 27th Annual Global Investment Conference fireside chat
▲First Patient DosedBRIUMVIApprovedTrial
Phase 3 trial for subcutaneous BRIUMVI commenced enrollment
relapsing forms of multiple sclerosis (RMS)source ↗
◆Oral PresentationPresentation
TG Therapeutics to participate in Cantor Global Healthcare Conference fireside chat
▲Quarterly UpdateCorporate
Completion of previously authorized $100 million share repurchase program
▲Quarterly UpdateBRIUMVIApprovedCorporate
Preliminary full year 2025 BRIUMVI U.S. net product revenue of ~$594 million
relapsing forms of multiple sclerosissource ↗
▲Partnership / LicenseBRIUMVIApprovedCorporate
Agreement with Neuraxpharm for ex-U.S. commercialization of BRIUMVI in RMS
relapsing forms of multiple sclerosis (RMS)source ↗
●Oral PresentationPresentation
Conference call to discuss Q2 2023 financial results and business outlook
▲Product LaunchBRIUMVIApprovedPost-Market
Commercial launch of BRIUMVI
relapsing forms of multiple sclerosissource ↗
Past FDA Catalysts and PDUFA Decisions
How TGTX actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2025-09-24 | BRIUMVI® (ublituximab-xiiy) | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
C53 / 100
Pipeline Score
$822M
Pipeline Value
$3.5B
Commercial Value
Overvalued
Valuation Signal
4
Drugs Scored
0.2x
rNPV / MCap
Top 14%
Small Cap(rank 93 of 660)
Percentile Rank
TG Therapeutics, Inc. carries a moderate pipeline score (53/100), with $1.3B risk-adjusted pipeline value, led by Azercabtagene zapreleucel in B-cell Mediated Autoimmune Disorders (Phase 1).
Commercial products (revenue basis: trailing 4 quarters of total revenue (10-K and 10-Q), to Jun 2026; product lines: last four quarters to Jun 2026 (10-K and 10-Q)) Revenue $799.5M x 4.4 = $3.5B
| Product | Revenue | Prior period | Change |
|---|---|---|---|
| BRIUMVI | $786M | $449M | +74.9% |
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Azercabtagene zapreleucel CAR-TNCT06680037 | B-cell Mediated Autoimmune Disorders | Phase 1 | RECRUITING | 100 | Jan 1, 2029 |
Clinical Trial Results
Readouts, endpoints and source filings for every TGTX program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| BRIUMVI | myasthenia gravis | Phase 1 | 2026-06-09 | 82%; mean >4 point improvement; n=11; mean baseline MG-ADL of 8.24; mean baseline QMG score of 12.0; median time to MCID of 30 days; mean 4.6 point improvement in MG-ADLRead More | TG Therapeutics Announces Positive Topline Phase 1 Data for Subcutaneous BRIUMVI in Patients with Myasthenia Gravis and Initiation of Potential Registration Directed Randomized Phase 2 TrialRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Charney Laurence NDirector | Sell | -5,000 168,640 held | $54.96 | 09/10/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in TGTX
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| SOLEUS CAPITAL MANAGEMENT, L.P. | 5.5 % (1.9 %) | 160.86 M | 2.93 M | -27.34% ( -1.10 M) |
TGTX Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-16 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How TGTX ranks across every disease it competes in
Competitive Position is a premium feature
See how TGTX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialTGTX News
TGTX▲ +3.2%today
TG Therapeutics Announces Schedule of Data Presentations at MSToronto2026
TG Therapeutics, Inc. has announced its presentation schedule for the 10th Joint ACTRIMS-ECTRIMS Meeting, MSToronto2026, taking place from October 21-23, 2026, in Toronto. The schedule includes a late-breaking oral presentation on initial results from a Phase 1 study of azer-cel for primary progressive multiple sclerosis (PPMS). Additionally, several presentations will focus on the company's product, BRIUMVI®.
Read more →TGTXTG Therapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
TG Therapeutics, Inc. will participate in the H.C. Wainwright 28th Annual Global Investment Conference from September 14-16, 2026. CEO Michael S. Weiss is scheduled for a fireside chat on September 14 at 12:00 PM ET. The event will be accessible via a live webcast on the company's website.
Read more →TGTXTG Therapeutics to Participate in the Cantor Global Healthcare Conference
TG Therapeutics, Inc. will participate in the Cantor Global Healthcare Conference from September 9-11, 2026. CEO Michael S. Weiss is scheduled for a fireside chat on September 9 at 11:30am ET. The event will be accessible via a live webcast on the company's website. TG Therapeutics focuses on developing treatments for B-cell diseases and has FDA approval for its product BRIUMVI.
Read more →TGTX▼ -11.3%on this news
TG Therapeutics Reports Second Quarter 2026 Financial Results and Raises BRIUMVI® Revenue Guidance
TG Therapeutics reported strong financial results for Q2 2026, with total global revenue of approximately $240 million. The company raised its full-year revenue guidance for BRIUMVI, anticipating U.S. net product revenue of $890 to $905 million. Positive results from the Phase 3 ENHANCE trial and advancements in subcutaneous BRIUMVI were highlighted, indicating a promising future for the company's pipeline.
Read more →TGTXTG Therapeutics to Host Conference Call on Second Quarter 2026 Financial Results and Business Update
TG Therapeutics, Inc. will host a conference call on August 3, 2026, at 8:30 AM ET to discuss its second quarter financial results and provide a business outlook for the remainder of the year. The call will be led by CEO Michael S. Weiss and will include a live webcast. Financial results will be announced in a press release prior to the call.
Read more →TGTXTG Therapeutics Announces Initiation of Phase 2 Trial Evaluating BRIUMVI in Patients with Treatment-Resistant Schizophrenia
TG Therapeutics has initiated a Phase 2 clinical trial for BRIUMVI (ublituximab-xiiy) in adults with treatment-resistant schizophrenia. The study aims to evaluate the efficacy and safety of BRIUMVI in approximately 60 participants who have not responded adequately to standard antipsychotic treatments. The trial is based on emerging evidence suggesting a role for B-cell depletion in managing schizophrenia symptoms.
Read more →TGTX▲ +5.9%on this news· ran to +21% by day 3
TG Therapeutics Announces Positive Topline Phase 1 Data for Subcutaneous BRIUMVI in Patients with Myasthenia Gravis and Initiation of Potential Registration Directed Randomized Phase 2 Trial
TG Therapeutics announced positive topline results from a Phase 1 study of subcutaneous BRIUMVI in patients with myasthenia gravis, showing that 82% of participants achieved a Minimal Clinically Important Difference in their MG-ADL scores. The company is initiating a Phase 2 trial to evaluate BRIUMVI as a maintenance therapy after induction with efgartigimod. This trial aims to assess the efficacy of BRIUMVI in maintaining clinical responses in MG patients.
Read more →TGTX▲ +9.5%on this news
TG Therapeutics Announces Positive Results from Phase 1 Trial Evaluating Subcutaneous BRIUMVI® (ublituximab-xiiy)
TG Therapeutics announced positive results from a Phase 1 trial for its subcutaneous formulation of BRIUMVI (ublituximab). The trial demonstrated good safety and tolerability, with pharmacokinetic data supporting a quarterly dosing regimen. The company anticipates that this formulation could become the first self-administered anti-CD20 therapy for multiple sclerosis, with Phase 3 results expected by early 2027.
Read more →TGTXTG Therapeutics to Participate in the Goldman Sachs 47th Annual Healthcare Conference
TG Therapeutics, Inc. will participate in the Goldman Sachs 47th Annual Healthcare Conference from June 8-10, 2026. CEO Michael S. Weiss is scheduled for a fireside chat on June 9 at 2:00 PM ET. A live webcast will be available on the company's website, enhancing accessibility for investors.
Read more →TGTXTG Therapeutics Announces Publication of Post-Hoc Data from the Phase 3 ULTIMATE I & II Trials in Treatment Naive Patients with Relapsing Forms of MS Published in Frontiers in Immunology
TG Therapeutics announced the publication of post-hoc data from the Phase 3 ULTIMATE I and II trials, showing that BRIUMVI (ublituximab) significantly reduced the annualized relapse rate in treatment-naïve patients with relapsing forms of multiple sclerosis. The findings indicate substantial improvements in clinical and MRI outcomes, supporting the early use of high-efficacy therapies.
Read more →TGTXTG Therapeutics to Participate in the Jefferies Global Healthcare Conference
TG Therapeutics will participate in the Jefferies Global Healthcare Conference from June 2-4, 2026. CEO Michael S. Weiss is scheduled to speak during a fireside chat on June 3 at 11:40 AM ET. The event will be accessible via a live webcast on the company's website. TG Therapeutics is known for its focus on treatments for B-cell diseases.
Read more →TGTXTG Therapeutics Announces Positive Topline Results from Phase 3 ENHANCE Trial
TG Therapeutics announced positive topline results from the Phase 3 ENHANCE trial, which evaluated a new single infusion regimen of BRIUMVI for treating relapsing forms of multiple sclerosis. The trial demonstrated bioequivalence between the new regimen and the existing two-infusion regimen, potentially streamlining patient treatment. A supplemental BLA filing is targeted for the second half of 2026.
Read more →TGTXTG Therapeutics Announces Data Presentations for BRIUMVI® at the 2026 Consortium of Multiple Sclerosis Centers Annual Meeting
TG Therapeutics announced data presentations for BRIUMVI at the 2026 Consortium of Multiple Sclerosis Centers annual meeting. The presentations will showcase findings from the ENABLE Phase 4 study, highlighting significant patient-reported outcomes and real-world data demonstrating effective disease control. The event will take place from May 27-29, 2026, in Charlotte, N.C.
Read more →TGTX▲ +16.3%on this news
TG Therapeutics Reports First Quarter 2026 Financial Results and Raises BRIUMVI Revenue Guidance
TG Therapeutics reported strong financial results for Q1 2026, with total global revenue of approximately $205 million, driven by BRIUMVI's U.S. net revenue of about $195 million. The company raised its full-year revenue guidance for BRIUMVI to between $885 million and $900 million, reflecting strong market demand and new patient starts. Additionally, TG Therapeutics announced ongoing clinical trials and a robust pipeline for BRIUMVI and other therapies.
Read more →TGTXTG Therapeutics to Host Conference Call on First Quarter 2026 Financial Results and Business Update
TG Therapeutics will host a conference call on May 6, 2026, at 8:30 AM ET to discuss its first quarter financial results and business outlook for the remainder of the year. CEO Michael S. Weiss will lead the call, which will also be available via live webcast. The company has FDA approval for its treatment BRIUMVI for multiple sclerosis.
Read more →TGTX▲ +5.6%on this news
TG Therapeutics Announces Data Presentations for BRIUMVI in Multiple Sclerosis at the American Academy of Neurology 2026 Annual Meeting
TG Therapeutics announced the presentation of new data on BRIUMVI at the AAN 2026 annual meeting. The findings from the ENABLE and ENHANCE studies emphasize the drug's effectiveness and safety for treating relapsing multiple sclerosis (RMS). The company aims to provide insights into optimized dosing and continue expanding clinical data supporting BRIUMVI as a treatment option.
Read more →TGTXData Published in Neurology and Therapy Demonstrate Significant Reductions in Relapse and MRI Activity with BRIUMVI® in People with Highly Active Relapsing Multiple Sclerosis
TG Therapeutics announced positive results from a pooled analysis of Phase 3 studies on BRIUMVI (ublituximab) for treating highly active relapsing multiple sclerosis. The data, published in Neurology and Therapy, demonstrated significant reductions in relapse rates and MRI activity compared to teriflunomide. The findings support the early use of BRIUMVI in patients at risk for rapid disease progression.
Read more →TGTXTG Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Raises BRIUMVI Revenue Guidance
TG Therapeutics reported strong financial results for Q4 and full year 2025, with total revenues of $192.6 million and $616.3 million, respectively. The company raised its revenue guidance for 2026 to approximately $875-900 million, driven by the success of its BRIUMVI product. CEO Michael S. Weiss highlighted the company's momentum and focus on future clinical milestones.
Read more →TGTXTG Therapeutics to Host Conference Call on Fourth Quarter and Full Year 2025 Financial Results and Business Update
TG Therapeutics will hold a conference call on February 26, 2026, to discuss its financial results for Q4 and the full year of 2025. CEO Michael S. Weiss will lead the call, which will also provide a business outlook for 2026. A live webcast will be available, and a recording will be accessible for 30 days post-call.
Read more →TGTXLong Term Data Published in JAMA Neurology Demonstrate Sustained Efficacy and Consistent Safety of BRIUMVI in Relapsing Multiple Sclerosis
TG Therapeutics announced the publication of five-year data from the Phase 3 ULTIMATE I and II studies on BRIUMVI for relapsing multiple sclerosis. The results indicate a low annualized relapse rate of 0.020 and a consistent safety profile over the treatment period. The findings support the long-term efficacy of BRIUMVI, emphasizing its role as a valuable treatment option for patients with relapsing MS.
Read more →About TG Therapeutics, Inc.
Headquarters2 GANSEVOORT STREET, 9TH FLOOR, NEW YORK, NY, 10014
BIOPHARMAWATCH ELITE PLUS
Trade the next TGTX catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime